ArticleJournal of nanobiotechnology2025
Chinese leek-derived extracellular vesicles ameliorate sarcopenia by regulating mitochondrial biogenesis and autophagy via AMPK and maintaining myosin homeostasis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Modulation of innate and adaptive immunity by pH-responsive nanozyme-like nanoparticles with high mobility for rheumatoid arthritis alleviation.Bioactive materials · 2026Article
- ASIV Attenuates Cisplatin-Induced Proximal Tubular Injury by Enhancing Mitochondrial Biogenesis and Mitophagy Through the ADRA1A/AMPK/FOXO3A Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Stem Cell and Stem Cell-Derived Extracellular Vesicles: Therapeutic Potential and Mechanistic Insights in Anti-Aging.Stem cell reviews and reports · 2026Review
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
- The Central Role of the AMPK/SIRT1/PGC-1α Signaling Axis in Skeletal Muscle Physiology and Pathology and Its Targeted Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Plant-derived extracellular vesicles as emerging cardioprotective agents for cardiovascular diseases.Journal of nanobiotechnology · 2026Review
- Plant-Derived Nanovesicles: A Comprehensive Review from Isolation to Clinical Translation-Unlocking Natural Nanocarriers for Biomedical Applications.Biomolecules · 2026Review
- Modulation of mitochondrial quality control in sepsis by traditional Chinese medicine: mechanistic insights and translational perspectives.Frontiers in pharmacology · 2026Review
- Plant-Derived Extracellular Vesicles for Nanomedicine in Cardiopulmonary Diseases: A Narrative Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Sarcopenia, a prevalent age-related degenerative disorder, poses significant challenges in geriatric care. Chinese leek demonstrates therapeutic potential against sarcopenia progression, with emerging evidence suggesting its extracellular vesicles (EVs) may mediate these effects. Notably, plant-derived EVs have garnered increasing attention due to their low immunogenicity and capacity for cross-kingdom molecular delivery. This study investigates Chinese leek-derived EVs (CL-EVs) as novel regulators of muscle homeostasis through multi-omics approaches. CL-EVs were isolated via differential ultracentrifugation and characterized using nanoparticle tracking analysis, TEM, and proteomic profiling. Using a dexamethasone (DEX)-induced C2C12 myotube atrophy model, we demonstrated CL-EVs' cellular internalization and dose-dependent restoration of myotube diameter. CL-EVs significantly alleviated DEX-induced mitochondrial impairment in C2C12 cells, evidenced by restored ATP production, reduced ROS levels, and stabilized mitochondrial membrane potential (MMP). Multi-omics analysis revealed CL-EVs activate the AMPK/SIRT1/PGC-1α axis, confirmed by Western blotting. Proteomic analysis identified selenium-associated proteins in CL-EVs. Expanding on selenocompounds' known anti-proteolytic effects through Akt modulation, we demonstrate CL-EVs attenuate myotube atrophy through dual mechanisms: inactivation of Akt/FoxO3a/Atrogin-1/MuRF1 proteolytic signaling and activation of mitochondrial biogenesis/mitophagy pathways, collectively improving muscle homeostasis. To investigate gut-muscle axis interactions, 16 S rDNA sequencing and untargeted metabolomic profiling were performed on fecal samples. CL-EVs treatment attenuated DEX-induced gut microbiota dysbiosis and correlated metabolic abnormalities in sarcopenic mice. This study establishes CL-EVs as novel regulators of muscle homeostasis through dual modulation of AMPK/SIRT1/PGC-1α activation and Akt/FoxO3a/Atrogin-1/MuRF1 inhibition. This innovative "multi-target & gut-muscle axis" paradigm provides a groundbreaking strategy for sarcopenia therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.